San Diego-Based Medical Device Company Sequenom Highlights Cost Savings and Team Responsiveness Using ClinCapture, Clinovo’s Open Source Electronic Data Capture (EDC) System
Sunnyvale, CA (PRWEB) November 27, 2013
Sequenom selected Clinovo among five shortlisted eClinical systems’ vendors for its open source Electronic Data Capture (EDC) system ClinCapture. Sequenom awarded Clinovo as their preferred vendor for the cost-efficiency of ClinCapture’s open source model and the team’s commitment to deadlines and budget.
Sequenom develops genetic disorder diagnostics. The medical device company focuses on prenatal and ophthalmological diseases and conditions. Sequenom has been using ClinCapture, Clinovo’s open source EDC system, as its system of choice to run its clinical trials since January 2012. ClinCapture was deployed on two clinical studies on their noninvasive prenatal test for detection of fetal chromosomal abnormalities.
Sequenom received the 1.0.3 release of ClinCapture in January 2013, which added significant functionality and enhanced ease-of-use. “The new system had all the changes and added features we requested, which truly made us feel listened to as customers”, explains Graham McLennan, Senior Director, Clinical Operations at Sequenom. “The improved interface of ClinCapture is so easy to use and much faster to learn for sites”, confirmed Sara Moellering, Senior Clinical Research Associate. The ease of use and flexibility of the system convinced Sequenom to keep on using Clinovo’s platform for its upcoming studies in a foreseeable future.
Sequenom’s team pointed out Clinovo’s excellent customer service and timely support. The diagnostic company needed a local and reactive California-based partner for facilitated communication and support. Clinovo proved reliable in regards to timely deliverables, while keeping steady costs and limited change orders “to things we truly requested”, explains Graham.
Prior to Clinovo, Sequenom couldn’t deploy and maintain software technologies to run its clinical trials due to high costs of proprietary systems. As a result, the diagnostic company had been largely using paper, which proved time-consuming and did not ensure the same quality level as Electronic Data Capture (EDC) systems. Traditional paper-based data collection methods are time-consuming, more expensive and can put data quality at risk.
Clinovo’s customers claim that ClinCapture significantly reduced their costs by more than 50%. ClinCapture is fully validated and 21 CFR Part 11, which ensures that data is collected in accordance with the latest regulations. ClinCapture features advanced functions such as One-Click Access, Dynamic Groups, and Calendared Events to collect data efficiently and minimize data entry errors. A 10-day free evaluation of the latest version of ClinCapture can be started on clinovo.com/clincapture.
Clinovo partners with life science companies to streamline their clinical trials, leveraging years of expertise in systems integration, open-source technology and industry standards. Clinovo provides Staffing Solutions, TechTrainings, eClinical Systems and Biometrics Services including Clinical Data Management, Electronic Data Capture, CDISC Mapping and Clinical and Statistical Programming.
Sequenom is a life sciences company committed to improving healthcare through revolutionary genomic and genetic analysis solutions. The medical device company, founded in 1994 and headquartered in San Diego, CA, develops innovative technologies, products, and diagnostic tests that target and serve discovery, clinical research, and molecular diagnostic markets. Sequenom Laboratories is a wholly-owned subsidiary of Sequenom. It has developed a broad range of genetic disorder diagnostics with a focus on prenatal and ophthalmological diseases and conditions. SensiGene™, MaterniT21™ PLUS, HerediT™, NextView™, and RetnaGene™ are molecular genetic laboratory-developed tests that provide early patient management information for obstetricians, geneticists, maternal fetal medicine specialists and ophthalmologists.
For the original version on PRWeb visit: http://www.prweb.com/releases/2013/11/prweb11375155.htm